In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. CRISPR Therapeutics AG ...

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By ...

Multisystemic smooth muscle dysfunction syndrome (MSMDS) is a rare condition associated with stroke, aortic dissection ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced insulin for months without the patient needing to take immunosuppressants.

Researchers have unveiled a new type of nanostructure that dramatically improves CRISPR delivery. Called lipid nanoparticle ...

It has long been understood that orchard automation is the key for industry’s profitability and sustainability. As part of ...

A study, published in the journal Frontiers in Genome Editing, outlines a method for editing single plant cells from sterile ...

The global CRISPR-based gene editing market size is projected to grow from USD 4.46 billion in 2025 to over USD 13.39 billion by 2034, expanding at a CAGR of 13%. Growth is fueled by advancements in ...

Flashpoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision-engineered structural ...

Researchers engineered a bespoke CRISPR-Cas9 gene-editing enzyme to develop a potential therapy for MSMDS, which ...

"Our technology reduces the off-target activity of Cas9 and increases its genome-editing specificity and clinical utility." The new tool—called LF N -Acr/PA—uses a protein-based delivery system to ...

CRISPR Therapeutics CRSP and Beam Therapeutics BEAM are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the first and only ...